This site is part of the Informa Connect Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC's registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 3099067.

TIDES USA: Oligonucleotide & Peptide Therapeutics
SEE YOU NEXT YEAR: May 7-10, 2023 | In-Person + Digital
San Diego, CA, USA

Somasekar Seshagiri, PhD
CEO and CSO at AntlerA Therapeutics


Sekar Seshagiri is leader in genomics and drug discovery. Prior to his current role as CEO and CSO of AntlerA, he spent over 20 years at Genentech where he was a Staff Scientist and Associate Director. During his tenure at Genentech, he established a state-of-the-art genomics laboratory where he conducted research in cancer and cell signaling areas to support drug discovery and development. He has authored and co-authored over 100 articles in peer-reviewed journals including Nature, Nature Genetics, Science, and Cancer Cell.

Agenda Sessions

  • AntlerA Wnt-agonist Antibody Therapeutics